As of September 30, 2024, the company had cash, cash equivalents and marketable securities of $202.8 million, which is expected to fund our operating expenses and capital expenditure requirements into the second half of 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Acrivon Therapeutics to presents data on deployment of AP3 platform
- Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline
- Acrivon announces initial patient dosing in Phase 1 trial of ACR-2316
- Acrivon Therapeutics price target raised to $28 from $25 at BMO Capital
- Acrivon Therapeutics: Promising Trial Results and FDA Clearance